160 related articles for article (PubMed ID: 22871636)
21. Dependence on the CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient.
Symons J; Vandekerckhove L; Hütter G; Wensing AM; van Ham PM; Deeks SG; Nijhuis M
Clin Infect Dis; 2014 Aug; 59(4):596-600. PubMed ID: 24759824
[TBL] [Abstract][Full Text] [Related]
22. HIV coreceptor phenotyping in the clinical setting.
Low AJ; Swenson LC; Harrigan PR
AIDS Rev; 2008; 10(3):143-51. PubMed ID: 18820716
[TBL] [Abstract][Full Text] [Related]
23. Characterization of CXCR4-using HIV-1 during primary infection by ultra-deep pyrosequencing.
Raymond S; Saliou A; Nicot F; Delobel P; Dubois M; Carcenac R; Sauné K; Marchou B; Massip P; Izopet J
J Antimicrob Chemother; 2013 Dec; 68(12):2875-81. PubMed ID: 23869053
[TBL] [Abstract][Full Text] [Related]
24. Appraising the performance of genotyping tools in the prediction of coreceptor tropism in HIV-1 subtype C viruses.
Crous S; Shrestha RK; Travers SA
BMC Infect Dis; 2012 Sep; 12():203. PubMed ID: 22938574
[TBL] [Abstract][Full Text] [Related]
25. Brief Report: HIV-1 Tropism During Primary Infections in France: 1996-2014.
Raymond S; Nicot F; Sauné K; Cazabat M; Pasquier C; Massip P; Marchou B; Delobel P; Izopet J
J Acquir Immune Defic Syndr; 2016 Aug; 72(4):376-9. PubMed ID: 26959188
[TBL] [Abstract][Full Text] [Related]
26. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
[TBL] [Abstract][Full Text] [Related]
27. The role of viral coreceptors and enhanced macrophage tropism in human immunodeficiency virus type 1 disease progression.
Gorry PR; Sterjovski J; Churchill M; Witlox K; Gray L; Cunningham A; Wesselingh S
Sex Health; 2004; 1(1):23-34. PubMed ID: 16335478
[TBL] [Abstract][Full Text] [Related]
28. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
[TBL] [Abstract][Full Text] [Related]
29. Phenotypic assays for the determination of coreceptor tropism in HIV-1 infected individuals.
Braun P; Wiesmann F
Eur J Med Res; 2007 Oct; 12(9):463-72. PubMed ID: 17933728
[TBL] [Abstract][Full Text] [Related]
30. The HIV coreceptor switch: a population dynamical perspective.
Regoes RR; Bonhoeffer S
Trends Microbiol; 2005 Jun; 13(6):269-77. PubMed ID: 15936659
[TBL] [Abstract][Full Text] [Related]
31. High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.
Nedellec R; Herbeck JT; Hunt PW; Deeks SG; Mullins JI; Anton ED; Reeves JD; Mosier DE
AIDS Res Hum Retroviruses; 2017 Mar; 33(3):234-245. PubMed ID: 27604829
[TBL] [Abstract][Full Text] [Related]
32. Genotypic coreceptor analysis.
Sierra S; Kaiser R; Thielen A; Lengauer T
Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 tropism dynamics and phylogenetic analysis from longitudinal ultra-deep sequencing data of CCR5- and CXCR4-using variants.
Sede MM; Moretti FA; Laufer NL; Jones LR; Quarleri JF
PLoS One; 2014; 9(7):e102857. PubMed ID: 25032817
[TBL] [Abstract][Full Text] [Related]
34. Co-receptor switch during HAART is independent of virological success.
Saracino A; Monno L; Cibelli DC; Punzi G; Brindicci G; Ladisa N; Tartaglia A; Lagioia A; Angarano G
J Med Virol; 2009 Dec; 81(12):2036-44. PubMed ID: 19856465
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 coreceptor usage, transmission, and disease progression.
Philpott SM
Curr HIV Res; 2003 Apr; 1(2):217-27. PubMed ID: 15043204
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy.
Weiser B; Philpott S; Klimkait T; Burger H; Kitchen C; Bürgisser P; Gorgievski M; Perrin L; Piffaretti JC; Ledergerber B;
AIDS; 2008 Feb; 22(4):469-79. PubMed ID: 18301059
[TBL] [Abstract][Full Text] [Related]
37. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1.
Tscherning C; Alaeus A; Fredriksson R; Björndal A; Deng H; Littman DR; Fenyö EM; Albert J
Virology; 1998 Feb; 241(2):181-8. PubMed ID: 9499793
[TBL] [Abstract][Full Text] [Related]
38. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression.
Raymond S; Delobel P; Mavigner M; Cazabat M; Encinas S; Souyris C; Bruel P; Sandres-Sauné K; Marchou B; Massip P; Izopet J
AIDS; 2010 Sep; 24(15):2305-12. PubMed ID: 20808203
[TBL] [Abstract][Full Text] [Related]
39. The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection.
Moore JP; Kitchen SG; Pugach P; Zack JA
AIDS Res Hum Retroviruses; 2004 Jan; 20(1):111-26. PubMed ID: 15000703
[TBL] [Abstract][Full Text] [Related]
40. Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission.
Chalmet K; Dauwe K; Foquet L; Baatz F; Seguin-Devaux C; Van Der Gucht B; Vogelaers D; Vandekerckhove L; Plum J; Verhofstede C
J Infect Dis; 2012 Jan; 205(2):174-84. PubMed ID: 22147802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
